Charles River Laboratories
CRL • NYSE
Charles River Laboratories is a medical - diagnostics & research company in the healthcare sector trading on NYSE, led by CEO James C. Foster, with a market cap of $7.8B.
CEOJames C. Foster
Next Earnings
Upcoming earnings announcement for Charles River Laboratories
Date
Wednesday, May 6, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.96
Revenue Estimate
$980.6M
Earnings History
Past 12 earnings reports for Charles River Laboratories
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | Q4 2025 | $2.39Est: $2.34 | +2.1% | $994.2MEst: $986.6M | +0.8% |  10-K |
| Nov 5, 2025 | Q3 2025 | $2.43Est: $2.33 | +4.3% | $1.0BEst: $988.3M | +1.7% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $3.12Est: $2.50 | +24.8% | $1.0BEst: $984.2M | +4.9% | 10-Q |
| May 7, 2025 | Q1 2025 | $2.34Est: $2.09 | +12.0% | $984.2MEst: $941.5M | +4.5% | 10-Q |
| Feb 19, 2025 | Q4 2024 | $2.66Est: $2.53 | +5.1% | $1.0BEst: $983.6M | +2.0% | 10-K |
| Nov 6, 2024 | Q3 2024 | $2.59Est: $2.43 | +6.6% | $1.0BEst: $976.0M | +3.3% | 10-Q |
| Aug 7, 2024 | Q2 2024 | $2.80Est: $2.39 | +17.2% | $1.0BEst: $1.0B | +0.6% | 10-Q |
| May 9, 2024 | Q1 2024 | $2.27Est: $2.07 | +9.7% | $1.0BEst: $991.7M | +2.1% | 10-Q |
| Feb 14, 2024 | Q4 2023 | $2.46Est: $2.40 | +2.5% | $1.0BEst: $991.3M | +2.2% | 10-K |
| Nov 8, 2023 | Q3 2023 | $2.72Est: $2.37 | +14.8% | $1.0BEst: $1.0B | +2.7% | — |
| Aug 9, 2023 | Q2 2023 | $2.69Est: $2.64 | +1.9% | $1.1BEst: $1.1B | +1.0% | 10-Q |
| May 11, 2023 | Q1 2023 | $2.78Est: $2.59 | +7.3% | $1.0BEst: $986.4M | +4.3% | — |